Inicio / Oncología / Abstracts de oncología / Stereotactic ablative body…

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

0 / 5 (0 votos)
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

The Lancet Oncology

Fecha de publicación: 1 de Enero de 2021

DOI: https://doi.org/10.1016/S1470-2045(20)30537-4

Autores: Anastasia Chalkidou, PhD , Thomas Macmillan, MSc, Mariusz T Grzeda, MSc, Prof Janet Peacock, PhD, Jennifer Summers, PhD, Saskia Eddy, MSc, Bola Coker, MSc, Hannah Patrick, FFPHM, Helen Powell, PhD, Lee Berry, Gareth Webster, PhD, Peter Ostler, FRCR, Peter D Dickinson, FRCR, Matthew Q Hatton, FRCR, Ann Henry, MD, Prof Stephen Keevil, PhD, Prof Maria A Hawkins, FRC, Prof Nick Slevin, FRCR, Nicholas van As, MD

Background: Stereotactic ablative body radiotherapy (SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is scarce. Additional evidence from a real-world setting is required. We present the results of a national study of patients with extracranial oligometastases undergoing SABR, representing the largest dataset, to our knowledge, on outcomes in this population so far.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.